Big-Name VCs Inject $80M Into Peanut Allergy Treatment
A young drugmaker with its sights set on easing deadly peanut allergies said Thursday it has raked in $80 million in fresh funding from big-name venture capitalists, a distinct vote of...To view the full article, register now.
Already a subscriber? Click here to view full article